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Abstract
Several mutations in the PALB2 gene (partner and localizer of BRCA2) have been associated with an
increased risk of breast cancer, including a founder mutation, 1592delT, reported in Finnish breast
cancer families. Although most often the risk is moderate, it doesn't exclude families with high-risk
mutations to exist and such observations have been reported. To see if high-risk PALB2-mutations
may be present in the geographically confined population of Iceland, linkage analysis was done on
111 individuals, thereof 61 breast cancer cases, from 9 high-risk non-BRCA1/BRCA2 breast cancer
families, targeting the PALB2 region. Also, screening for the 1592delT founder mutation in the 9
high-risk families and in 638 unselected breast cancer cases was performed. The results indicate no
linkage in any of the high-risk families and screening for the 1592delT mutation was negative in all
samples. PALB2 appears not to be a significant factor in high-risk breast cancer families in Iceland
and the 1592delT mutation is not seen to be associated with breast cancer in Iceland.
Background
Breast cancer is among the most frequent human cancers
and the most common carcinoma in women in the West-
ern world, where one out of every ten women is affected.
A dominant pattern of inheritance is evident in approxi-
mately 5–10% of all breast cancers. To date, two main
breast cancer susceptibility genes have been identified;
BRCA1 and BRCA2 accounting for nearly half of high-
incidence breast cancer families and an increased relative
risk of breast cancer by 10- to 20- fold [1,2]. Other known
breast cancer susceptibility genes such as CHEK2 and ATM
have a more moderate penetrance with an increased life-
time risk of about 2- to 3- fold [2].
The PALB2 gene is a BRCA2 binding factor that ensures
BRCA2  function as a tumor suppressor and has been
shown to cause Fanconi anemia subtype FA-N when bial-
lelic germ-line mutations occur in the gene [3-5]. Recent
studies have reported several mutations in PALB2 to be
associated with an increased risk of breast cancer [6-9].
One is the founder mutation 1592delT which has been
found to be present at a significantly elevated frequency in
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breast cancer families in Finland, resulting in a 4-fold
increased risk to mutation carriers [6]. Although predis-
posing PALB2 mutations generally appear to cause mod-
erate risk of breast cancer [8], mutations have also been
found in strong hereditary breast cancer families [7,9] and
might thus be worthwhile searching for by linkage analy-
sis in e.g. geographically confined populations.
Only two BRCA1 and BRCA2 mutations have been found
in the Icelandic population, BRCA2 999del5 and BRCA1
G5193A, both being founder mutations explaining a large
proportion of familial breast cancer in Iceland [10]. The
BRCA2  999del5 mutation is much more frequent,
accounting for around 40% of the hereditary cases and
found in about 8% of unselected breast cancer cases and
0,4% of population based control [11]. A BRCA2 999del5
mutation is also the most frequently occurring BRCA1/2
mutation in Finland [12], and haplotype analysis of Finn-
ish and Icelandic BRCA2 999del5 families did not exclude
the possibility of a common ancient origin of the muta-
tion [13]. The BRCA1 G5193A mutation however is very
rare, found in less than 2,5% of hereditary breast cancer
families and in 0,2% of unselected breast cancer cases
[14]. The extreme frequency figures of these two founder
mutations reflect low genetic diversity in the Icelandic
population. The Icelandic population is a very young one,
the country being settled by a few thousand founders
about 1100 years ago. Low genetic diversity is probably
explained by the relatively homogeneous group of set-
tlers, and genetic drift resulting from repeated population
bottlenecks due to diseases and famines [15,16].
The aim of this study is to find out if the PALB2 gene is
likely to play a significant role in breast cancer susceptibil-
ity in Iceland, by linkage analysis of high-risk non-
BRCA1/2 breast cancer families with markers closely sur-
rounding the PALB2 gene to test the possibility of a highly
penetrant mutation, and by screening for the Finnish
1592delT founder mutation in the family members and a
large group of unselected breast cancer patients.
Results and Discussion
No evidence of linkage in the PALB2 region was found in
any of the high risk breast cancer families [see Additional
file 1]. The two markers flanking the PALB2  gene,
D16S420 (~0.58 Mb centromeric to PALB2) and
D16S412 (~0.45 Mb telomeric to PALB2), showed highly
negative Lod scores of total -4.18 (θ = 0,00001) and -2.69
(θ = 0,00001).
Several PALB2 mutations have been identified and one of
them has been found as a recurrent mutation, 1592delT in
Finland [6]. In light of the possible common ancient ori-
gin of the BRCA2 999del5 mutation in the Finnish and
the Icelandic population we decided to screen for the
Finnish PALB2 founder mutation, 1592delT, in Icelandic
breast cancer cases. The mutation was not detected in 638
unselected breast cancer cases nor in any of the 111 family
members of the nine high risk breast cancer families.
The results of this study suggest that PALB2 is not a signif-
icant contributor to breast cancer in high-risk breast can-
cer families in Iceland. Furthermore, the results show that
the 1592delT mutation appears not to be associated with
breast cancer in the Icelandic population, and if occurring
it would be very rare. However the results can not exclude
the possibility that other PALB2 mutations causing low or
moderate breast cancer risk exist in the Icelandic popula-
tion. To determine that, it would be necessary to perform
a PALB2 mutation screening or SNP analysis in a large
cohort of breast cancer cases.
Methods
Study population
The sample set consisted of: 111 individuals from nine
high-risk non-BRCA1/BRCA2  breast cancer families
(Table 1), 38 controls to evaluate allele frequencies in the
linkage analysis, and 638 unselected breast cancer cases
diagnosed in the period 1987–2003. All patients contrib-
uting to the research have given their informed consent.
The research has been approved by the Icelandic Data Pro-
jection Authority and the National Bioethics Committee.
Laboratory Analysis
Blood samples were lyzed and DNA extracted from nuclei
according to Miller et al [17]. DNA from paraffin-embed-
ded tissue was extracted as described by Jönsson et al [18]
and from fresh-frozen tissue using the Wizard Genomic
DNA Purification Kit (Promega).
Table 1: Summary of the main clinical characteristics of the 9 
high risk breast cancer families






Mean age at first
diagnosis
 years (range)
1 5 6(4) 61.8(44-76)
2 5 11(5) 49.4 (44–64)
3* 10 14 (10) 57.4 (50–88)
4* 9 17 (8) 54.2 (38–75)
5* 11 20 (9) 49.7 (29–70)
6 6 11 (5) 57.5 (35–79)
7 8 8 (6) 61.1 (42–79)
8 5 11 (5) 49.6 (30–66)
9 9 13 (9) 51.8 (30–77)
Total 68 111 (61) 54.6 (29–88)
*Co-occurrence of ovarian cancer in the family (one family member 
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To evaluate linkage in the families the following microsat-
ellite markers were used: D16S3036, D16S412, D16S420
and D16S3068 (primer sequences are available in the
UCSC Genome Browser, genome assembly March 2006)
[19]. Primers to screen for the 1592delT mutation were as
in Erkko et al [6]. All the primers were purchased from
MWG Biotech and each forward primer was 5' labeled
with either FAM or HEX fluorophore reporter. The PCR
conditions for all primer pairs were: 3 minutes incubation
at 94°C, followed by 35 cycles of 94°C for 30 seconds,
55°C for 45 seconds, 72°C for 45 seconds and a final
extension at 72°C for 10 minutes, except for the 1592delT
primers for which the annealing temperature was 64°C
instead of 55°C. The PCR products were analysed using
an automated ABI PRISM 3130 × l Genetic Analyzer, alle-
les were called automatically using the GeneMapper soft-
ware v4.0 and checked manually.
Statistical analysis
The Genetic Analysis System software (GAS) was used to
check the genotyping data for Mendelian inconsistencies
within the families. Genotypes which were inconsistent
with Mendelian inheritance were reviewed. Any ambigu-
ous genotypes were dropped. Allele frequencies for the
microsatellite markers were calculated using founder indi-
viduals from the families as well as the control individuals
using the Gconvert program [20]. Evidence for linkage
was evaluated using parametric linkage analysis methods.
Two-point LOD scores were calculated using the
FASTLINK program, assuming a rare (frequency = 0.0033)
dominantly inherited disease allele. Age-dependant liabil-
ity classes were defined using the modified CASH model
[21,22].
Abbreviations
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